RRM is being increasingly undertaken,14,15,16 and is cost-effective compared with BC screening and medical prevention among BRCA1/BRCA2/PALB2 PV carriers at varying surgery ages.17,18 However, its cost-effectiveness at the 30% lifetime BC risk level is unassessed, and the scientific rationale for this BC risk threshold remains unclear. This evidence concerns the gene BRCA2 and breast cancer.